Insmed to present 11 abstracts from across its respiratory portfolio at the american thoracic society 2025 international conference

—new  analyses from the phase 3 aspen study examining efficacy and safety of brensocatib across a variety of prespecified subgroups— —data from aspen post-hoc  analysis evaluating changes in lung function in bronchiectasis patients who did or did not experience pulmonary exacerbations in the trial— — data on health status improvements over time following culture conversion in patients with mycobacterium avium complex (mac) lung disease— bridgewater, n.j. , march 25, 2025 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present 11 abstracts from across its respiratory portfolio at the american thoracic society (ats) 2025 international conference, taking place may 18-21, 2025, in san francisco.
INSM Ratings Summary
INSM Quant Ranking